Altimmune Reports Positive Phase 2 Results for Pemvidutide in Alcohol Use Disorder

RECLAIM Trial Achieves Primary Efficacy Endpoint

Altimmune disclosed that the RECLAIM Phase 2 trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week when comparing the pemvidutide 2.4 mg dose to placebo in patients with moderate to severe alcohol use disorder. The filing indicates this represents a meaningful clinical finding in a therapeutic area where treatment options remain limited. The company emphasized that the reduction in heavy drinking days constitutes a core measure of efficacy for AUD therapeutics and serves as a critical benchmark for regulatory advancement.

The statistical significance of the primary endpoint improvement positions pemvidutide as a potentially differentiated treatment approach. The announcement highlights that the 2.4 mg dose was selected for evaluation based on prior clinical data and safety considerations. This dosage level appears to have demonstrated the optimal balance between efficacy and tolerability in the study population, a distinction that may be important for future development and commercialization planning.

Secondary Endpoints and FDA Registrational Markers

Beyond the primary endpoint, the RECLAIM trial showed positive results across important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and achievement of zero heavy drinking days. The filing notes that both of these endpoints carry significance as FDA registrational endpoints, suggesting they align with regulatory expectations for pivotal trial design. This alignment with FDA criteria may facilitate discussions with regulators regarding the pathway forward for pemvidutide development in AUD.

The trial also demonstrated a reduction in phosphatidyl ethanol levels, a biomarker used to assess alcohol consumption and abstinence in clinical research. The combination of behavioral endpoints and biomarker improvements provides multiple lines of evidence supporting the drug candidate's mechanism of action in AUD. These layered positive results across diverse outcome measures strengthen the overall clinical profile presented to investors and regulators.

Safety and Tolerability Profile in the Study Population

Altimmune reported that a generally favorable safety and tolerability profile was observed throughout the RECLAIM trial. The filing does not provide specific details regarding adverse event rates, types of adverse events encountered, or discontinuation rates due to safety concerns. The company's characterization of the safety profile as "generally favorable" suggests that pemvidutide was well-tolerated at the 2.4 mg dose in this patient population, though investors should note that comprehensive safety data would typically be detailed in more extensive clinical reports.

The tolerability findings are particularly important in the AUD indication, where patients may face competing health considerations and potential medication adherence challenges. A favorable safety profile may support patient compliance and clinical utility if the drug advances to later-stage development and potential commercialization. The company did not disclose specific safety metrics, comparative safety data versus placebo, or any safety signals that may have emerged during the trial in this announcement.

Pemvidutide's Mechanism as a Dual Receptor Agonist

Pemvidutide is characterized in the filing as an investigational balanced glucagon/GLP-1 dual receptor agonist. This dual mechanism of action differentiates pemvidutide from other therapeutics in development for AUD and represents a novel approach to treating alcohol use disorder. The glucagon/GLP-1 pathway may influence neural reward circuits, appetite regulation, and metabolic functions that could theoretically intersect with alcohol use behaviors and cravings, though the filing does not elaborate on the underlying biological rationale.

The dual agonist approach is distinct from medications currently approved for AUD, which typically work through different mechanisms such as opioid antagonism or GABA modulation. If pemvidutide advances successfully through development, it could represent an alternative treatment option for patients who do not respond to or tolerate existing therapies. The novelty of the mechanism may also support intellectual property protection and potential commercial differentiation in the AUD market.

End-of-Phase 2 Meeting Strategy with FDA

The announcement indicates that Altimmune plans to request an End-of-Phase 2 meeting with the FDA based on the RECLAIM trial results. This regulatory step, also known as a Phase 2 exit meeting, provides an opportunity for the company to meet with FDA reviewers to discuss the clinical development program and gain feedback on the proposed path to a potential pivotal trial. The filing does not provide details regarding the timing of this meeting request or the specific topics the company plans to address with regulators.

The decision to pursue an End-of-Phase 2 meeting suggests management confidence in the trial data and an intent to advance pemvidutide toward Phase 3 development. During such meetings, companies typically discuss trial design considerations for pivotal studies, endpoint selection, patient population definitions, and regulatory expectations for approval. The FDA's feedback from this meeting could influence the design and scope of future trials required for potential regulatory approval.

Clinical Development Timeline and Regulatory Pathway

The filing does not provide specific guidance regarding the timeline for the proposed End-of-Phase 2 FDA meeting or the anticipated schedule for future clinical development activities. Investors may be watching for subsequent announcements regarding the timing of regulatory interactions and the company's plans for advancing pemvidutide through Phase 3 evaluation. The regulatory pathway for AUD therapeutics can vary based on FDA feedback and the specific endpoints the company proposes for pivotal trials.

The successful Phase 2 results position pemvidutide to progress further in clinical development, assuming the FDA meeting yields supportive guidance. The company will likely need to determine whether a single pivotal trial or multiple Phase 3 studies will be required for a New Drug Application submission. These decisions, informed by the upcoming FDA meeting, will shape the company's development strategy and resource allocation over the coming years.

Alcohol Use Disorder Market Context

Alcohol use disorder represents a significant public health challenge affecting millions of individuals in the United States and globally. Current FDA-approved treatments for AUD include naltrexone, acamprosate, and disulfiram, each with distinct mechanisms and variable patient acceptance. The filing does not quantify the potential market size for pemvidutide or provide comparative efficacy data versus existing treatments. However, the positive Phase 2 results suggest pemvidutide could become an additional treatment option if it successfully completes further development and receives regulatory approval.

The therapeutic landscape for AUD has seen limited innovation in recent decades relative to other conditions, creating potential opportunities for differentiated therapies. The filing indicates that pemvidutide's dual glucagon/GLP-1 mechanism represents a novel approach distinct from approved medications. If the compound proves effective and safe in pivotal trials, it could address unmet needs in AUD treatment and appeal to patients and providers seeking alternatives to existing pharmacotherapies.

Investor Considerations and Next Steps

The positive RECLAIM Phase 2 announcement represents a significant clinical milestone for Altimmune and the pemvidutide program in AUD. Investors may be monitoring the company's progress toward the planned End-of-Phase 2 FDA meeting and subsequent regulatory interactions. The timing and outcome of this meeting could provide additional clarity regarding the regulatory path forward and the company's development priorities. The immediate share price impact was not clear from available public information at the time of this disclosure.

Key developments to monitor include the FDA meeting outcome, decisions regarding Phase 3 trial design, patient enrollment timelines, and any additional clinical or safety data from the RECLAIM study. The company may also provide updates regarding resource allocation, partnership discussions, or financing activities related to continued pemvidutide development. Investors should note that positive Phase 2 results do not guarantee success in pivotal trials or ultimate regulatory approval, and further development carries inherent scientific, regulatory, and commercial risks.

Company Background and Location

Altimmune, Inc. is incorporated in Delaware and maintains its principal executive offices in Gaithersburg, Maryland. The company's common stock trades on the NASDAQ Global Market under the ticker symbol ALT. The filing was signed on July 28, 2026, by Gregory Weaver, Chief Financial Officer of Altimmune, and represents the company's current report disclosures under applicable securities regulations. No additional changes to corporate contact information or former addresses were noted in the announcement.

The July 28, 2026 announcement follows established procedures for communicating material clinical trial results to investors and the public. The company furnished the information under Item 7.01 of Regulation FD Disclosure, meaning it was disclosed simultaneously to all market participants without selective release. This regulatory framework ensures that investors have equal access to material information regarding the company's clinical development programs.